The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids

The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids

Monoagent DNA-alkylating chemotherapies like dacarbazine are among a paucity of medical treatments for advanced carcinoid tumors, but are limited by host toxicity and intrinsic chemoresistance through the base excision repair (BER) pathway via poly (ADP-ribose) polymerase (PARP). Hence, inhibitors o...

Full description

Bibliographic Details
Main Authors:	Somnay, Yash, Lubner, Sam, Gill, Harpreet, Matsumura, Jon Blake, Chen, Herbert
Format:	Online
Language:	English
Published:	2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083201/

Similar Items

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
by: Guillot, Clément, et al.
Published: (2014)

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
by: Mariano, Germano, et al.
Published: (2015)

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
by: Lemasson, Benjamin, et al.
Published: (2016)

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
by: Ji, Jiuping, et al.
Published: (2011)

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
by: Barazzuol, Lara, et al.
Published: (2013)

Chrysin suppresses the achaete-scute complex-like1 and alters the neuroendocrine phenotype of carcinoids
by: Somnay, Yash R., et al.
Published: (2015)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
by: Munasinghe, Wijith, et al.
Published: (2016)

Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
by: Tuli, Richard, et al.
Published: (2014)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
by: Balvers, Rutger K, et al.
Published: (2015)

PARP inhibitors
by: Anwar, Maheen, et al.
Published: (2015)

miR-888: Hit it when you see it!
by: Bader, Andreas G
Published: (2014)

Correction: High-Content, High-Throughput Analysis of Cell Cycle Perturbations Induced by the HSP90 Inhibitor XL888
by: Lyman, Susan K., et al.
Published: (2011)

PARP inhibitors are not all equal
by: Dent, Paul
Published: (2013)

PARP inhibitors: the race is on
by: Brown, Jessica S, et al.
Published: (2016)

PARP inhibitors in ovarian cancer
by: Cibula, David, et al.
Published: (2015)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
by: Gill, Sonja J., et al.
Published: (2015)

Resistance to PARP-Inhibitors in Cancer Therapy
by: Montoni, Alicia, et al.
Published: (2013)

Predicting PARP inhibitor sensitivity and resistance
by: Bebb, D. Gwyn, et al.
Published: (2012)

Role of Biomarkers in the Development of PARP Inhibitors
by: Ganguly, Bratati, et al.
Published: (2016)

An update on PARP inhibitors for the treatment of cancer
by: Benafif, Sarah, et al.
Published: (2015)

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
by: Mizugaki, Hidenori, et al.
Published: (2015)

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
by: Ko, Tun Kiat, et al.
Published: (2014)

Preparation and Characterization of Metformin Hydrochloride — Compritol 888 ATO Solid Dispersion
by: Jagdale, SC, et al.
Published: (2011)

Catalogue of Dated and Dateable Manuscripts c.888‐1600 in London Libraries
Published: (2004)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
by: Heym, Peter-Paul, et al.
Published: (2012)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
by: Cang, Shundong, et al.
Published: (2015)

3′-5′ Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo
by: Toledano, Elie, et al.
Published: (2012)

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome
by: Oluwaseun Shogbesan, et al.
Published: (2018-08-01)

Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female
by: Cogen, Jonathan D., et al.
Published: (2016)

Advances in using PARP inhibitors to treat cancer
by: Kummar, Shivaani, et al.
Published: (2012)

Effect of HO-3089 PARP inhibitor on inflammatory response
by: Nemeth, M, et al.
Published: (2011)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
by: Reinbolt, Raquel E., et al.
Published: (2013)

PARP inhibitors: its role in treatment of cancer
by: Chen, Alice
Published: (2011)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
by: Ricks, Tiffany K., et al.
Published: (2015)

PARP1 Inhibitors: antitumor drug design
by: Malyuchenko, N. V., et al.
Published: (2015)

PARP inhibitors: current status and implications for anticancer therapeutics
by: Usmani, Hadi, et al.
Published: (2013)

New treatment option for ovarian cancer: PARP inhibitors
by: Meehan, Robert S., et al.
Published: (2016)

Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH
by: Abdullah, I., et al.
Published: (2017)

Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH
by: Abdullah, I., et al.
Published: (2018)

In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine
by: Chen, Kuan-Chung, et al.
Published: (2014)